# Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

> **NCT00227591** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Essential Thrombocythemia
- Polycythemia Vera
- Primary Myelofibrosis

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** prednisone
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00227591
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227591, "Lenalidomide and Prednisone in Treating Patients With Myelofibrosis". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00227591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*